Mechanisms of local immunoresistance in glioma
- PMID: 19944963
- DOI: 10.1016/j.nec.2009.08.008
Mechanisms of local immunoresistance in glioma
Abstract
Even though the central nervous system (CNS) was conventionally defined as "immunologically privileged", new discoveries have demonstrated the role of the immune system in neurologic disease and illness, including gliomas. Brain tumor immunotherapy is an exciting and revived area of research, in which neurosurgeons have taken a major position. Despite the ability to induce a tumor-specific systemic immune response, the challenge to effectively eradicate intracranial gliomas remains mainly because of tumor-induced immunoresistance. This article gives an overview of the immunologic responses that occur in the CNS and their potential role in brain tumors. The main cellular and molecular mechanisms that mediate tumor escape from natural immune surveillance are also covered in this article. Glioma cells have been shown to diminish the expression of danger signals necessary for immune activation and to increase the concentration of immunosuppressive factors in the tumor microenvironment, which results in T-cell anergy or apoptosis. Finally, the authors discuss most of the over-expressed oncogenic signaling pathways that cause tumor tolerance.
Similar articles
-
Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.Neurol Clin. 1985 Nov;3(4):901-17. Neurol Clin. 1985. PMID: 2417097 Review.
-
Dendritic cell-based immunotherapy for malignant gliomas.Expert Rev Neurother. 2005 Jul;5(4):497-508. doi: 10.1586/14737175.5.4.497. Expert Rev Neurother. 2005. PMID: 16026233 Review.
-
Tumor antigens in astrocytic gliomas.Glia. 1995 Nov;15(3):244-56. doi: 10.1002/glia.440150306. Glia. 1995. PMID: 8586461 Review.
-
Immunotherapy for glioma: promises and challenges.Neurosurg Clin N Am. 2012 Jul;23(3):357-70. doi: 10.1016/j.nec.2012.05.001. Neurosurg Clin N Am. 2012. PMID: 22748649 Review.
-
[Cellular immunotherapy for malignant glioma].Nihon Rinsho. 2005 Sep;63 Suppl 9:557-62. Nihon Rinsho. 2005. PMID: 16201581 Review. Japanese. No abstract available.
Cited by
-
Mesenchymal stem cell-like properties of CD133+ glioblastoma initiating cells.Oncotarget. 2016 Jun 28;7(26):40546-40557. doi: 10.18632/oncotarget.9658. Oncotarget. 2016. PMID: 27244897 Free PMC article.
-
High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.CNS Neurosci Ther. 2020 Mar;26(3):309-318. doi: 10.1111/cns.13254. Epub 2019 Nov 11. CNS Neurosci Ther. 2020. PMID: 31710183 Free PMC article.
-
Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.Purinergic Signal. 2016 Jun;12(2):303-12. doi: 10.1007/s11302-016-9505-8. Epub 2016 Feb 24. Purinergic Signal. 2016. PMID: 26910734 Free PMC article.
-
Genetically modified T cells to target glioblastoma.Front Oncol. 2013 Dec 31;3:322. doi: 10.3389/fonc.2013.00322. Front Oncol. 2013. PMID: 24427741 Free PMC article. Review.
-
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.J Immunother. 2012 Jun;35(5):385-9. doi: 10.1097/CJI.0b013e3182562d59. J Immunother. 2012. PMID: 22576343 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical